Andere talen G1 Therapeutics, Inc.

Aandelen

GTHX

US3621LQ1099

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 07-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,01 ^USD	+1,35%		-8,79%	-1,31%

28/05	G1 Therapeutics, Inc. Kondigt de presentatie aan van rijpe Fase 2 klinische onderzoeksresultaten	CI
23/05	G1 Therapeutics kondigt komende presentatie aan op de American Society of Clinical Oncology Meeting van 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	06/06
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/06
G1 THERAPEUTICS, INC. - MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL AND TOLERABILITY OBSERVED IN PATIENTS RECEIVING TRILACICLIB IN COMBINATION WITH A TROP2 ANTIBODY-DRUG CONJUGATE	29/05
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)	28/05
G1 Therapeutics, Inc. Announces the Presentation of Mature Phase 2 Clinical Trial Results	28/05
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting	23/05
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting	23/05
G1 THERAPEUTICS TO PARTICIPATE IN TD COWEN'S 5TH ANNUAL ONCOLOGY INNOVATION SUMMIT	23/05
G1 THERAPEUTICS AND DEIMOS BIOSCIENCES ANNOUNCE GLOBAL LICENSE AGREEMENT FOR LEROCICLIB FOR RADIOPROTECTIVE USES	23/05
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit	22/05
Sector Update: Health Care Stocks Lower Premarket Wednesday	22/05
G1 Therapeutics Grants Deimos Biosciences License to Market Anti-Radiation Treatment -- Shares Up Pre-Bell	22/05
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses	22/05
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses	22/05
Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	14/05
G1 Therapeutics : May 2024 Corporate Presentation	08/05
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/05
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M	01/05
G1 Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2024	01/05
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights	01/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen G1 Therapeutics, Inc.

Aandelen

GTHX

US3621LQ1099

Andere talen

Filters